Thabet Qapaja News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Advanced therapies for inflammatory bowel disease, namely small molecules and biologic therapies, did not increase the risk of a major adverse cardiovascular event or venous thromboembolism.

United statesBritish columbiaThabet qapajaMiguel regueiroCleveland clinic digestive disease instituteAmerican college of gastroenterologyCleveland clinicAmerican collegeScientific meetingDigestive diseaseSmall molecule therapies are not associatedIncreased major adverse cardiovascular eventsPropensity matched cohortInflammatory bowel diseaseAdvanced therapies